Table 2 Patients outcomes according to treatment with dexamethasone
|  | Overall (n = 151) | DEXA+ (n = 84) | DEXA− (n = 67) | p value |
|---|---|---|---|---|
At least 1 VAP and/or 1 BSI, n (%) | 100 (66) | 56 (67) | 44 (66) | 0.59 |
At least 1 VAP, n (%) | 91 (60) | 53 (63) | 38 (57) | 0.43 |
Second VAP episode, n (%) | 34 (23) | 22 (26) | 12 (18) | 0.23 |
Third VAP episode, n (%) | 15 (10) | 11 (13) | 4 (6) | 0.15 |
At least 1 BSI, n (%) | 44 (29) | 24 (29) | 20 (30) | 0.86 |
Second BSI episode, n (%) | 14 (9) | 7 (8) | 7 (10) | 0.66 |
Third BSI episode, n (%) | 3 (2) | 1 (1) | 2 (3) | 0.59 |
Invasive MV duration before first VAP, days, median (IQR) | 6 (3–12) | 5 (3–10) | 9 (4–15) | 0.02 |
Mortality at D28, n (%) | 25 (17) | 14 (17) | 11 (16) | 0.94 |
Mortality at D60, n (%) | 39 (26) | 23 (28) | 16 (24) | 0.57 |
Hospital mortality, n (%) | 46 (32) | 28 (35) | 18 (27) | 0.27 |
VFD D28, median (IQR) | 0 (0–18) | 9 (0–21) | 0 (0–11) | 0.009 |
VFD D60, median (IQR) | 27 (0–49) | 37(0–53) | 25 (0–43) | 0.12 |
Duration of mechanical ventilation, days, median (IQR) | 17 (9–37) | 14 (7–39) | 24 (12–36) | 0.008 |
ICU length of stay, days, median (IQR) | 24 (15–45) | 20 (11–44) | 32 (17–46) | 0.01 |
Hospital length of stay, days, median (IQR) | 31 (20–49) | 28 (18–47) | 33 (24–53) | 0.06 |